Os therapies incorporatedOSTX.US Overview
US StockHealthcare
(No presentation for OSTX)
OSTX Overall Performance
OSTX AI Analysis & Strategy
OSTX Recent Performance
-
Os therapies incorporated
0.81%
Avg of Sector
-1.14%
S&P500
OSTX PowerScanner
OSTX Key Information
OSTX Valuation Metrics
OSTX Earnings Table
OSTX Profile
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.